The need for cognitive health solutions
Cognitive function naturally declines with age, and MCI—a transitional state marked by noticeable memory and thinking difficulties—affects aged people. MCI is a known risk factor for dementia and Alzheimer’s disease, yet there is currently no approved treatment for this condition. This unmet need has driven demand for safe, effective and natural interventions that support mental clarity, focus and cognitive resilience in older adults.
Somin-On: distinctive standardisation
What sets Somin-On apart is standardisation to not less than 2% Sominone content, verified by HPLC. Sominone is the principal active metabolite identified as responsible for Somin-On’s cognitive effects.
Ashwagandha has a long history in Ayurveda for managing stress, anxiety and cognitive support, but Somin-On’s focus on Sominone allows for a more targeted and clinically validated approach to cognitive health.
Clinical evidence: improvements in cognitive function
The efficacy of Somin-On for cognitive function was demonstrated in a randomised, double-blind, placebo-controlled study published in The Journal of Psychopharmacology in 2025. Forty adults with MCI were assigned to receive either 250 mg of Somin-On daily or a placebo for 60 days, with cognitive assessments at baseline, 30 and 60 days.
Key findings:
-
Memory enhancement: Somin-On supplementation led to significant improvements in immediate, general and working memory, as measured by the Wechsler Memory Scale-III (WMS-III), outperforming the placebo group at both 30 and 60 days.
-
Visuospatial processing: Participants in the Somin-On group showed marked improvement in visuospatial processing, with Shepard Mental Rotation Test scores rising by 12% at 30 days and 32% at 60 days from baseline.
-
Global cognitive assessments: Somin-On users experienced significant gains in the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), with increases of 15% and 19% respectively at 60 days compared to baseline, indicating broader cognitive function benefits.
-
Attention and processing speed: The study concluded that Somin-On is effective in improving attention and information processing speed, crucial aspects of cognitive function for individuals with MCI.
Safety and broader context
The clinical trial reported no significant adverse effects, supporting Somin-On’s safety for use in older adults with MCI.
Conclusion
Somin-On™ represents a novel, clinically validated approach to cognitive health, driven by the potent withanolide Sominone. Its ability to improve memory, attention and information processing speed in adults with mild cognitive impairment positions it as a valuable tool for supporting healthy cognitive ageing. As the population ages and the prevalence of cognitive decline rises, Somin-On offers a safe, natural and effective solution for maintaining cognitive function and overall brain health.
“The supplementation of Somin-On is an effective remedy to improve the immediate, general and working memory, as well as cognitive functions like attention and information processing speed in adults with MCI.”
